Skip to content

COMET T1 CRC Feasibility study

COMputer aidEd characterization of T1 ColoRectal Carcinoma – real-time feasibility study. - COMET T1 CRC Feasibility study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON58215
Enrollment
30
Registered
2025-08-06
Start date
2026-04-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer Bowel cancer

Interventions

An AI-system (CADx) which will be capable of diagnosing T1 CRCs, estimating invasion depth of CRC and which includes an algorithm-based treatment advise.&nbsp

Sponsors

Catharina Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 18 years or olderAble to give informed consentThe patient has a planned colonoscopy for the endoscopic resection of a known large colorectal polyp or a suspected colorectal malignancy.

Exclusion criteria

Exclusion criteria: Patients with inadequate bowel preparations after adequate washing, suctioning and other cleaning manoeuvres have been performed by the endoscopist: BPPS 1 or 2 in the segment of the polyp or carcinoma. The BPPS of the other segments is not explicitly graded. Patient with an active IBD in the same segment as the polyp or carcinoma.Patient with familial adenomatous polyposis (FAP)Patients who have a written objection in their patient file for participation in scientific research.Patients with a recurrence of a polyp or malignancy after earlier resection.When a biopsy of the lesion has occurred before video of the lesion is performed.No pathology of the lesion is obtained.

Design outcomes

Primary

MeasureTime frame
Feasibility of the CADx system regarding interface, latency and the absence of technical flaws.

Secondary

MeasureTime frame
The diagnostic performance of the CADx system compared to the diagnostic performance of endoscopists, using histopathology as gold standard. Diagnostic performance will be measured as sensitivity, specificity, negative predictive value, positive predictive value, diagnostic accuracy and the area under the ROC curve.Accuracy of the CADx system in estimating the invasion depth, using histopathology as gold standard.Evaluating if the CADx system is capable of providing an accurate treatment advice compared to the most appropriate treatment based on histopathology, lesion location, and lesion size.

Countries

Netherlands

Contacts

Public ContactE.J. Schoon

Catharina Ziekenhuis

erik.schoon@catharinaziekenhuis.nl0402399111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)